Stock Analysis
- United Kingdom
- /
- Personal Products
- /
- LSE:HLN
Haleon First Quarter 2024 Earnings: EPS Beats Expectations
Haleon (LON:HLN) First Quarter 2024 Results
Key Financial Results
- Revenue: UK£2.92b (down 2.2% from 1Q 2023).
- Net income: UK£423.0m (up 8.7% from 1Q 2023).
- Profit margin: 14% (up from 13% in 1Q 2023). The increase in margin was driven by lower expenses.
- EPS: UK£0.046 (up from UK£0.042 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Haleon EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in the United Kingdom.
Performance of the British Personal Products industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - Haleon has 1 warning sign we think you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Haleon might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About LSE:HLN
Haleon
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.